*RC110 may still be validated as FTO/CP by Nagler/Dominissini prior to any strategic licensing.
The strategic licensing angle is my best guess forward based on the data the company has released, not the data the company has on hand.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-205
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |